Research programme: integrin antagonists - sigma-tauAlternative Names: ST-1646
Latest Information Update: 29 Sep 2010
At a glance
- Originator Ronzoni Institute for Chemical and Biochemical Research; sigma-tau SpA; University of Bari; University of Milan
- Class Cyclic peptides
- Mechanism of Action Angiogenesis inhibitors; Integrin alphaVbeta3 antagonists; Integrin alphaVbeta5 antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Solid tumours